Amylyx Pharmaceuticals Inc AMLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
-
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
-
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
-
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
-
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
-
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
-
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
-
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Trading Information
- Previous Close Price
- $29.10
- Day Range
- $27.55–29.28
- 52-Week Range
- $10.83–41.14
- Bid/Ask
- $27.00 / $28.09
- Shares Outstanding
- 125.51M
- Market Cap
- $3.52B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 136
- Website
- https://www.amylyx.com
Valuation
|
Metric
|
AMLX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 13.08 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AMLX
Financial Strength
|
Metric
|
AMLX
|
|---|---|
Quick Ratio | 11.86 |
Current Ratio | 12.12 |
Interest Coverage | — |
Quick Ratio
AMLX
Profitability
|
Metric
|
AMLX
|
|---|---|
Return on Assets (Normalized) | −42.88% |
Return on Equity (Normalized) | −47.13% |
Return on Invested Capital (Normalized) | −49.84% |
Return on Assets
AMLX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|Q!>?$nn! | LOCK|xPm< | $66B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|M<tmk#Mg | LOCK|y?!< | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|QF&%#l | LOCK|^?n | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|<&P#&WY | LOCK|#V | $29B | |||
| Viatris Inc
VTRS
| LOCK|^>>w$R | LOCK|k# | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|^% | LOCK|$V | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|?%?dd%# | LOCK|@Y@ | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|S%r?dd | LOCK|X$# | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|BPxJk&f | LOCK|@P&v | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|ms?z%!N | LOCK|?#$ | $2B |
United States